Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker KURA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m o… NCT07007312 · Acute Myeloid Leukemia (AML) Ziftomenib, Placebo | KURA Kura Oncology, Inc. | Phase 3 | Recruiting | 1,300 | Nov 2031 | Registry ↗ |
| Nov 10, 2026 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML… NCT07929740 · Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute Ziftomenib, Ziftomenib | KURA Kura Oncology, Inc. | Phase 1 | Not yet recruiting | 126 | Feb 28, 2029 | Registry ↗ |
| Oct 27, 2026 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Strom… NCT06655246 · Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Str… ziftomenib, imatinib mesylate | KURA Kura Oncology, Inc. | Phase 1 | Recruiting | 135 | Jun 2029 | Registry ↗ |
| Oct 14, 2026 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410 · Solid Tumors With HRAS Alterations, Non Small Cell Lung Can… Darlifarnib, Cabozantinib | KURA Kura Oncology, Inc. | Phase 1 | Recruiting | 300 | Jan 2027 | Registry ↗ |
| Sep 8, 2026 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous… NCT04997902 · HNSCC Tipifarnib, Alpelisib | KURA Kura Oncology, Inc. | Phase 1/2 | Completed | 45 | Aug 29, 2025 | Registry ↗ |
| Aug 20, 2026 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myelo… NCT06001788 · AML, AML With Mutated NPM1 Ziftomenib, Fludarabine | KURA Kura Oncology, Inc. | Phase 1 | Recruiting | 171 | Dec 2026 | Registry ↗ |
| Jun 29, 2026 | Expanded Access to Ziftomenib NCT05738538 · Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Ac… ziftomenib | KURA Kura Oncology, Inc. | — | Available | — | — | Registry ↗ |
| Jun 29, 2026 | Expanded Access to Tipifarnib NCT04809233 · HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Tipifarnib | KURA Kura Oncology, Inc. | — | Available | — | — | Registry ↗ |
| May 13, 2026 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia NCT04067336 · Advanced Malignant Neoplasm, Acute Myeloid Leukemia Ziftomenib, Midazolam | KURA Kura Oncology, Inc. | Phase 1/2 | Active, not recruiting | 263 | Oct 16, 2028 | Registry ↗ |
| Mar 13, 2026 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Aza… NCT05735184 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation Ziftomenib, Venetoclax | KURA Kura Oncology, Inc. | Phase 1 | Recruiting | 420 | Apr 2030 | Registry ↗ |
| Jul 31, 2024 | Tipifarnib in Subjects With Myelodysplastic Syndromes NCT02779777 · Myelodysplastic Syndromes Tipifarnib | KURA Kura Oncology, Inc. | Phase 2 | Terminated | 16 | Aug 28, 2018 | Registry ↗ |
| Jul 17, 2024 | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leuke… NCT02807272 · Leukemia, Myelomonocytic, Chronic Tipifarnib | KURA Kura Oncology, Inc. | Phase 2 | Completed | 44 | Nov 30, 2020 | Registry ↗ |
| Jul 11, 2024 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations NCT02383927 · Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cance… Tipifarnib | KURA Kura Oncology, Inc. | Phase 2 | Completed | 63 | Dec 14, 2020 | Registry ↗ |
| Jun 26, 2024 | Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Ha… NCT02464228 · Relapsed or Refractory Peripheral T-Cell Lymphoma Tipifarnib | KURA Kura Oncology, Inc. | Phase 2 | Completed | 65 | Mar 31, 2021 | Registry ↗ |
| Jun 21, 2024 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on… NCT03719690 · HRAS Gene Mutation, HNSCC Tipifarnib, HRAS Detection Assay | KURA Kura Oncology, Inc. | Phase 2 | Completed | 296 | May 2, 2023 | Registry ↗ |
| Sep 21, 2023 | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies NCT04865159 · Advanced Solid Tumor Tipifarnib | KURA Kura Oncology, Inc. | Phase 1 | Terminated | 6 | May 2, 2023 | Registry ↗ |
| Mar 6, 2023 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer NCT05693090 · NSCLC Tipifarnib, Osimertinib | KURA Kura Oncology, Inc. | Phase 1 | Withdrawn | 0 | Jul 27, 2027 | Registry ↗ |
| Sep 20, 2021 | First-in-Human Study of KO-947 in Non-Hematological Malignancies NCT03051035 · Advanced Malignant Neoplasm KO-947 | KURA Kura Oncology, Inc. | Phase 1 | Terminated | 61 | Jun 2, 2020 | Registry ↗ |
18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances